Other Pipelines
We set development priorities based on market size, unmet medical needs, technical differentiation and development feasibility, and continually discover and develop competitive follow-on programs with the goal of early-stage out-licensing.
CU71
- Route
- Oral
- Indication
- Neurodegenerative diseases
- Development approach
- Development of therapies addressing endothelial dysfunction and blood–brain barrier (BBB) dysfunction
- Development status
- Discovery
CU72
- Route
- Oral
- Indication
- Idiopathic pulmonary fibrosis
- Development approach
- AI-driven development of next-generation therapies addressing unmet needs in current treatments for idiopathic pulmonary fibrosis
- Development status
- DiscoverySelected in 2026 for the Ministry of SMEs and Startups’ collaborative pharmaceutical–bio venture R&D program
CU73
- Route
- Oral
- Indication
- Thrombotic diseases
- Development approach
- Development of novel oral small-molecule therapies for thrombotic diseases
- Development status
- Discovery
CU03
- Route
- Oral
- Indication
- Age-related macular degeneration
- Development approach
- A multi-target therapeutic approach to macular degeneration
- Development status
- Korea Phase 2a clinical study report (CSR) received (2022.01)
CU104
- Route
- Oral
- Indication
- Ulcerative colitis
- Development approach
- Indication expansion of CU06 for ulcerative colitis
- Development status
- Phase 2a IND approvals in the U.S. and EuropeDevelopment strategy under review in alignment with CU06 global partnering
CU106
- Route
- Oral
- Indication
- Immuno-oncology combination therapy
- Development approach
- Indication expansion of CU06 for combination with cancer immunotherapies
- Development status
- Phase 1 completed in the U.S.Development strategy under review in alignment with CU06 global partnering
MT-105
- Route
- Intravenous
- Indication
- Inflammatory bowel disease
- Development approach
- Development of novel therapies targeting multiple pathological factors in inflammatory bowel disease
- Development status
- Discovery
MT-202
- Route
- Intravenous · Bispecific antibody
- Indication
- Ischemic stroke
- Development approach
- Combining PDI inhibition and Tie2 activation to inhibit thrombus formation and protect the vascular endothelium
- Development status
- Discovery
MT-40X
- Route
- Intravenous
- Indication
- Cancer
- Development approach
- Development approach to be disclosed
- Development status
- Discovery
MT-501
- Route
- Intravenous · Bispecific antibody
- Indication
- Vasculitis
- Development approach
- Tie2 activation and C5-axis inhibition for vascular stabilization and inflammation control
- Development status
- Discovery
CP01
- Route
- Oral
- Indication
- Canine chronic kidney disease (CKD)
- Development approach
- An endothelial dysfunction blocker for chronic kidney disease in dogs
- Development status
- Phase 3 study in dogs ongoing in Korea
CP02
- Route
- Oral
- Indication
- Feline chronic kidney disease (CKD)
- Development approach
- An endothelial dysfunction blocker for chronic kidney disease in cats
- Development status
- Discovery